The strongest established prostate cancer risk factors are increasing age, family history, inherited genetic susceptibility and ancestry-associated risk. Age has the largest population-level effect: prostate cancer is uncommon in younger men and becomes increasingly common later in life. Having an affected father or brother can more than double relative risk, with risk increasing further when several relatives are affected or cancer occurred at a young age. Pathogenic variants such as BRCA2, HOXB13 and selected DNA-repair genes can substantially increase risk in some families. By contrast, associations with obesity, diet, smoking, metabolic health and environmental exposures are generally smaller, more complex or less certain.
A risk factor changes probability; it does not predict an individual’s future with certainty. Relative risk tells us how one group’s risk compares with another group’s risk, while absolute risk describes the actual probability over a defined period. For context, the American Cancer Society currently estimates that about 1 in 8 U.S. men will be diagnosed with prostate cancer during their lifetime, but an individual’s probability can be meaningfully lower or higher depending on age, family history, ancestry, inherited variants and competing health factors.
01Which Prostate Cancer Risk Factors Are Most Clearly Established?
Age is the strongest common risk factor
Prostate cancer is strongly age-dependent.
The American Cancer Society reports that prostate cancer is rare in men younger than 40 and that the chance of diagnosis rises rapidly after age 50. Approximately 6 in 10 diagnosed prostate cancers occur in men aged 65 or older.
Age matters because prostate cells accumulate biological and genetic changes over many years, while age-related changes in the prostate environment may also influence whether latent abnormal cells become clinically detectable disease.
Age is therefore not simply a demographic association—it is a central component of prostate-cancer risk assessment.
What does ancestry tell us about risk?
Prostate-cancer incidence differs between populations.
In the United States and other Western settings, men of African ancestry—particularly Black men—have higher prostate-cancer incidence than many other population groups and are more often diagnosed at younger ages.
The explanation should not be reduced to “race causes prostate cancer.”
Observed differences can reflect overlapping influences from:
- inherited genetic susceptibility;
- specific ancestry-associated risk variants;
- environmental exposures;
- access to early detection and specialist care;
- differences in treatment;
- social determinants of health;
- and other population-level factors.
EAU guidance specifically cautions that outcomes in men of African ancestry may reflect biological, environmental, social and healthcare influences, not a single causal mechanism.
Why does geography matter?
Prostate-cancer incidence varies substantially across countries.
Part of that variation reflects:
- how frequently PSA testing is performed;
- population age structure;
- diagnostic intensity;
- genetic ancestry;
- environmental exposures;
- and healthcare access.
Migration studies also suggest that environment and lifestyle may contribute because prostate-cancer incidence can change across generations after migration.
An ancestry-associated increase in population incidence cannot tell an individual whether he has cancer. It is used as one element of a broader risk profile and can influence when informed PSA-based early detection is discussed.
What is the baseline lifetime risk in the United States?
The American Cancer Society currently estimates that approximately 1 in 8 U.S. men will be diagnosed with prostate cancer during their lifetime.
That figure is a population average.
It combines men with:
- different ages;
- different genetic backgrounds;
- different family histories;
- different screening exposure;
- and different competing causes of death.
It should therefore never be applied directly as one person’s predicted probability.
02How Do Family History and Inherited Genetics Change Prostate Cancer Risk?
A first-degree family history meaningfully increases risk
Family history is one of the most clinically useful risk signals.
A first-degree relative means a:
- father;
- brother;
- or son.
The American Cancer Society states that having a father or brother with prostate cancer more than doubles the risk of developing the disease.
NCI data similarly indicate an approximate two- to threefold relative-risk increase across studied populations.
Which family-history patterns are more concerning?
Risk tends to rise when:
- several close relatives have prostate cancer;
- the affected relatives were diagnosed at younger ages;
- prostate cancer occurred across multiple generations;
- there is metastatic or lethal prostate cancer in the family;
- or the same side of the family includes breast, ovarian, pancreatic, colorectal, uterine or other cancers suggestive of an inherited cancer syndrome.
The age at diagnosis matters because prostate cancer beginning unusually early is more likely to raise suspicion for inherited susceptibility than a single diagnosis late in life.
Familial prostate cancer is not always a single-gene syndrome
A family can show clustering of prostate cancer without one identifiable high-risk pathogenic variant.
Families may share:
- many common genetic variants;
- environmental exposures;
- health behaviors;
- patterns of PSA testing;
- or combinations of these factors.
EAU guidance separates broad familial clustering from more clearly hereditary patterns involving several cases, successive generations or unusually young diagnoses.
Which inherited genes are important?
Several germline pathogenic variants are associated with prostate-cancer susceptibility.
Important genes include:
- BRCA2;
- BRCA1;
- HOXB13;
- ATM;
- CHEK2;
- and mismatch-repair genes associated with Lynch syndrome, including MSH2, MLH1, MSH6 and PMS2.
BRCA2 has one of the clearest hereditary associations
BRCA genes are often associated publicly with breast and ovarian cancer, but they are also relevant to prostate cancer.
EAU evidence summaries estimate that pathogenic BRCA2 variants are associated with roughly a 2.5- to 4.6-fold relative risk of prostate cancer overall, with substantially higher relative risk reported for early-onset disease in some studies.
BRCA2-associated prostate cancers are also more likely, on average, to show aggressive clinical features than prostate cancers in non-carriers.
This does not mean every BRCA2 carrier develops prostate cancer.
What is HOXB13?
HOXB13 was the first gene identified specifically in connection with hereditary prostate-cancer susceptibility.
The best-studied pathogenic variant, G84E, occurs predominantly in men of European ancestry and is associated with several-fold increased prostate-cancer risk.
NCI notes that the magnitude of risk varies according to:
- family history;
- age;
- geographic population;
- and the specific variant.
This is an important reminder that even a “high-risk gene” does not carry one universal risk number for every carrier.
What does Lynch syndrome have to do with prostate cancer?
Lynch syndrome is caused by pathogenic variants in DNA mismatch-repair genes.
It is best known for increasing colorectal and endometrial cancer risk, but affected families can also have increased prostate-cancer susceptibility.
The strength of association can vary by the specific mismatch-repair gene, with MSH2 particularly relevant in several studies.
What are polygenic risk scores?
Not all inherited susceptibility comes from rare high-impact mutations.
Hundreds of common single-nucleotide variants each have a very small effect on prostate-cancer risk. When combined mathematically, these variants can generate a polygenic risk score.
EAU guidance notes that polygenic scores are associated with absolute prostate-cancer risk, but they currently do not replace established clinical risk assessment or PSA-based pathways.
A pathogenic germline variant changes risk; it does not diagnose cancer. A BRCA2 or HOXB13 result may justify earlier detection discussions and can matter for relatives, but PSA, MRI and biopsy remain separate parts of determining whether prostate cancer is actually present.
03What Lifestyle, Metabolic and Environmental Factors Are Associated With Prostate Cancer?
The evidence is much less certain than for age or family history
Prostate cancer has been studied in relation to hundreds of dietary, metabolic, occupational and behavioral exposures.
That does not mean each association is causal.
EAU guidance concludes that although numerous environmental and dietary associations have been reported, current evidence does not support a specific dietary or preventive strategy proven to prevent prostate cancer.
Does obesity increase prostate cancer risk?
The relationship is complicated.
Obesity does not consistently increase the overall chance of being diagnosed with prostate cancer.
However, several studies associate obesity with:
- greater risk of high-grade or aggressive disease;
- more advanced prostate cancer;
- and higher prostate-cancer-specific mortality.
For example, EAU cites REDUCE trial analyses in which obesity was associated with a lower probability of low-grade cancer but a higher probability of high-grade cancer.
That distinction is why “obesity causes prostate cancer” is too crude a statement.
What about metabolic syndrome and diabetes?
Data on metabolic syndrome are mixed.
EAU describes the overall association as weak, with somewhat stronger signals in aggressive disease.
Type 2 diabetes is particularly difficult to interpret because different large analyses have produced conflicting associations, including no association or even lower observed prostate-cancer diagnosis rates.
No one should attempt to alter diabetic treatment in order to influence prostate-cancer risk.
Does smoking cause prostate cancer?
Smoking is not one of the strongest established causes of developing prostate cancer.
Most epidemiological studies have not shown a large increase in overall prostate-cancer incidence among smokers.
However, smoking has been associated with:
- more aggressive tumor characteristics;
- worse outcomes;
- and higher prostate-cancer mortality.
EAU cites meta-analytic evidence associating current cigarette smoking with about a 24% higher relative risk of prostate-cancer death.
This is an association with outcome and mortality—not proof that smoking is responsible for most prostate cancers.
What about dairy products and calcium?
Some observational studies have associated high dairy or calcium intake with a small increase in prostate-cancer risk.
Other studies have been inconsistent.
Neither EAU nor major cancer organizations recommend extreme dietary calcium restriction as a prostate-cancer prevention strategy.
Calcium remains important for bone health, especially later in life.
Does eating tomatoes or taking lycopene prevent prostate cancer?
No supplement has been proven to prevent prostate cancer reliably.
Lycopene-rich dietary patterns have shown associations with lower risk in some observational studies, but results have not been sufficiently consistent to establish a preventive effect from lycopene supplements.
Vitamin E deserves a special caution
The Selenium and Vitamin E Cancer Prevention Trial—SELECT—was designed to test whether supplements could prevent prostate cancer.
Instead, vitamin E supplementation alone was associated with a statistically significant increase in prostate-cancer risk.
That trial is an important example of why a supplement that appears biologically plausible should not be assumed to prevent cancer.
Does vasectomy raise prostate cancer risk?
Current EAU guidance lists vasectomy among proposed associations that have been disproved as a meaningful prostate-cancer risk factor.
A man should therefore not interpret a past vasectomy as evidence that prostate cancer is likely.
Does frequent ejaculation prevent prostate cancer?
Some observational research has associated higher ejaculation frequency with lower prostate-cancer incidence.
EAU cites an association of approximately 20% lower risk among men reporting at least 21 ejaculations per month compared with 4–7 per month in one large observational dataset.
However:
- this is observational evidence;
- it does not establish a causal mechanism;
- and ejaculation frequency is not prescribed as a validated prostate-cancer prevention treatment.
Does testosterone replacement increase prostate cancer risk?
Current EAU evidence does not support the idea that appropriately prescribed testosterone supplementation in hypogonadal men increases prostate-cancer risk.
That is different from the established role of androgen signaling in the biology of an existing prostate cancer.
Men using testosterone still require appropriate prostate assessment based on age, health, symptoms and individual risk.
Current evidence does not support vasectomy as a meaningful prostate-cancer risk factor.
That is not supported as a simple causal rule. EAU evidence does not show increased prostate-cancer risk from testosterone supplementation in appropriately selected hypogonadal men.
Observational dietary associations do not establish that a supplement prevents prostate cancer.
No. Family history increases probability but does not make cancer inevitable.
Preventive health still matters even when prostate-specific causality is uncertain. Maintaining a healthy weight, avoiding tobacco, remaining physically active and following a balanced diet are important for cardiovascular health, diabetes prevention and overall cancer prevention. The evidence is simply not strong enough to promise that one lifestyle change will specifically prevent prostate cancer.
04How Should Prostate Cancer Risk Affect PSA Testing and Genetic Evaluation?
Risk factors matter because early prostate cancer is often silent
Many localized prostate cancers cause no symptoms.
That makes risk assessment particularly important: age, family history, ancestry and inherited variants can help identify men in whom discussion of earlier PSA-based detection is reasonable.
The symptom pattern is covered separately in Prostate Cancer Symptoms.
EAU uses different starting ages for different risk groups
Current EAU guidance recommends offering informed early PSA testing from approximately:
- age 50 for men without additional recognized risk factors;
- age 45 for men with a family history of prostate cancer diagnosed before age 60;
- age 45 for men of African descent;
- and age 40 for men carrying a pathogenic BRCA2 variant.
These are guideline entry points for discussion—not dates on which every person must automatically undergo repeated testing.
What happens after the first PSA?
The starting age is only one component of an early-detection strategy.
The actual PSA value can determine the interval before the next test.
Current EAU guidance supports longer intervals in men with reassuring baseline PSA levels and closer follow-up when baseline PSA indicates greater future risk.
If PSA is elevated, the next step is not automatically biopsy.
Evaluation may include:
- repeating PSA when a transient elevation is plausible;
- considering prostate volume and PSA density;
- using prostate MRI;
- using a validated risk calculator;
- or using selected blood or urine biomarkers before deciding whether biopsy is warranted.
The broader testing pathway is covered in PSA Testing and What Happens After a High PSA?.
Who should consider genetic counseling?
Germline testing is not needed for every man undergoing prostate-cancer screening.
Genetic counseling becomes more relevant when a family history includes:
- multiple relatives with prostate cancer;
- prostate cancer diagnosed before age 60;
- relatives who died from prostate cancer at a young age;
- known BRCA or other high-risk variants;
- multiple cancers on the same side of the family;
- or combinations of prostate, breast, ovarian, pancreatic or Lynch-associated cancers.
EAU recommends genetic counseling before germline testing.
Why can genetic testing matter after prostate cancer is diagnosed?
Inherited genetic information can have consequences beyond estimating who develops cancer.
In selected patients it can affect:
- risk assessment for relatives;
- screening recommendations within the family;
- understanding the likelihood of aggressive disease;
- and, in advanced prostate cancer, eligibility for certain molecularly targeted treatments.
Does family history change the meaning of a PSA result?
The laboratory PSA concentration itself does not change because someone has an affected brother.
What changes is the pre-test probability.
For example, the same borderline PSA value may lead to different levels of concern in:
- a man with no known family history and a reassuring prior PSA;
- versus a man with several first-degree relatives diagnosed with aggressive prostate cancer at young ages.
This is why modern prostate-cancer assessment combines biomarker results with personal risk rather than relying on a single universal PSA cutoff.
Age, family history, ancestry and pathogenic variants help decide when testing should start and how cautiously an abnormal result should be interpreted. Cancer is still diagnosed through the prostate-cancer evaluation pathway, not from the risk factor itself.
→Prostate Cancer Risk Factors: Evidence at a Glance
| Factor | Evidence strength / direction | What current evidence suggests | Important limitation |
|---|---|---|---|
| Increasing age | Strong ↑ | One of the most important population-level risk factors; incidence rises markedly after midlife. | Age does not identify which individual has cancer. |
| Father or brother with prostate cancer | Strong ↑ | Having a first-degree affected relative roughly doubles or more than doubles relative risk in large datasets. | Most men with family history still require ordinary diagnostic confirmation. |
| Several affected relatives | Stronger ↑ | Risk increases with the number of affected relatives, particularly young-onset disease. | Family clustering is not always due to one high-risk gene. |
| BRCA2 pathogenic variant | Strong ↑ | EAU estimates RR approximately 2.5–4.6 overall, with larger relative effects in early-onset disease. | Penetrance is incomplete; carrying BRCA2 does not guarantee prostate cancer. |
| HOXB13 pathogenic variant | Strong ↑ | Several-fold increased susceptibility, especially described for G84E in men of European ancestry. | Risk depends on variant, ancestry, age and family history. |
| Lynch syndrome / MMR genes | Established ↑ | Mismatch-repair pathogenic variants are associated with increased prostate-cancer susceptibility. | Magnitude varies among genes and families. |
| African ancestry | Population ↑ | Higher incidence and younger diagnosis are observed in several Western populations. | Genetic, environmental, social and healthcare factors all contribute; “race” is not a single biological mechanism. |
| Obesity | Complex | Not clearly associated with higher overall diagnosis, but linked in some studies to aggressive disease and mortality. | Detection effects and metabolic confounding complicate interpretation. |
| Smoking | Outcome ↑ | Not a major established cause of overall incidence, but associated with aggressive features and prostate-cancer mortality. | Mortality association is different from incidence risk. |
| High dairy / calcium intake | Possible small ↑ | Some studies report modest association. | Causality is uncertain; no recommendation to eliminate appropriate calcium intake. |
| Vitamin E supplements | Trial ↑ | SELECT found increased prostate-cancer risk with vitamin E supplementation alone. | This does not mean dietary vitamin E from normal food has the same effect. |
| Vasectomy | Not established | Current guideline evidence does not support a meaningful increased prostate-cancer risk. | Older observational reports created persistent public concern. |
| Lycopene supplements | Not proven ↓ | No reliable evidence that supplements prevent prostate cancer. | Dietary observational associations do not prove supplement efficacy. |
| Higher ejaculation frequency | Observed ↓ | Some observational cohorts report lower diagnosis rates. | Association does not establish a preventive treatment. |
| Testosterone therapy in hypogonadal men | No clear ↑ | EAU evidence does not show increased prostate-cancer risk from appropriately prescribed replacement therapy. | Men still require appropriate prostate monitoring and individualized assessment. |
?Common Questions About Prostate Cancer Risk
| Question | Practical answer |
|---|---|
| What is the biggest prostate cancer risk factor? | Increasing age is one of the strongest common population-level risk factors. |
| At what age does prostate cancer risk increase? | It is uncommon before age 40 and becomes substantially more common after age 50. |
| Does having a father with prostate cancer increase my risk? | Yes. A first-degree family history meaningfully increases relative risk. |
| Is a brother with prostate cancer relevant? | Yes. Brother history is a first-degree family-history risk factor and some datasets show particularly strong associations. |
| What if several relatives had prostate cancer? | Risk generally rises as more close relatives are affected, especially when diagnoses occurred at young ages. |
| Does prostate cancer on my mother’s side count? | Yes. Relevant inherited variants can be passed through either parent, so both maternal and paternal family histories matter. |
| Does a family history of breast cancer matter? | It can, particularly when the pattern suggests hereditary breast/ovarian cancer syndrome involving BRCA1 or BRCA2. |
| Does pancreatic cancer in the family matter? | It can be relevant in families being assessed for BRCA-associated cancer susceptibility. |
| What gene has a strong prostate cancer association? | BRCA2 is among the clearest inherited high-risk genes relevant to prostate cancer. |
| Does having BRCA2 mean I will get prostate cancer? | No. It increases probability but does not make prostate cancer inevitable. |
| What is HOXB13? | A prostate-development gene in which certain rare pathogenic variants are associated with hereditary prostate-cancer susceptibility. |
| Can Lynch syndrome increase prostate cancer risk? | Yes. Pathogenic mismatch-repair variants associated with Lynch syndrome can increase susceptibility. |
| Are Black men at greater prostate cancer risk? | Higher incidence and younger diagnosis are observed among Black men in several Western populations, but the difference reflects interacting genetic, environmental, social and healthcare factors rather than one simple racial cause. |
| Does obesity cause prostate cancer? | The overall incidence relationship is unclear, but obesity is associated in some studies with more aggressive disease and prostate-cancer mortality. |
| Does smoking cause prostate cancer? | Smoking is not a strong established cause of overall prostate-cancer incidence, but it is associated with worse prostate-cancer outcomes and mortality. |
| Does eating dairy cause prostate cancer? | Some studies suggest a small association with high dairy or calcium intake, but causality is not established. |
| Can vitamin E prevent prostate cancer? | No. In the SELECT randomized trial, vitamin E supplementation actually increased prostate-cancer risk. |
| Does vasectomy cause prostate cancer? | Current guideline evidence does not support vasectomy as a meaningful prostate-cancer risk factor. |
| Does frequent ejaculation prevent prostate cancer? | Some observational research shows an association with lower incidence, but it has not been established as a preventive treatment. |
| Does testosterone replacement cause prostate cancer? | Current EAU evidence does not show an increased risk from appropriately prescribed testosterone supplementation in hypogonadal men. |
| Can a healthy lifestyle guarantee I will avoid prostate cancer? | No. Many of the strongest risk factors—age, family history and inherited genetics—cannot be modified. |
| When should someone at higher risk discuss PSA testing? | EAU suggests informed PSA testing from age 45 for qualifying family history or African descent and from age 40 for BRCA2 carriers, compared with age 50 for men without additional recognized risk factors. |
| Does family history mean I need a biopsy? | No. Family history changes baseline probability and testing strategy; biopsy decisions depend on PSA, examination, MRI and the overall risk assessment. |
| Should everyone have genetic testing? | No. Germline testing is targeted toward patients or families with patterns suggesting inherited cancer susceptibility. |
ΣSummary
- Prostate cancer risk is probabilistic rather than deterministic.
- Increasing age is one of the strongest common risk factors.
- Prostate cancer is uncommon in men younger than 40.
- Incidence rises substantially after age 50.
- Approximately 6 in 10 U.S. prostate cancers are diagnosed in men aged 65 or older.
- The American Cancer Society estimates an average U.S. lifetime diagnosis risk of about 1 in 8 men.
- The 1-in-8 figure is a population average rather than an individual prediction.
- Family history is an established prostate-cancer risk factor.
- A father or brother with prostate cancer more than doubles relative risk in American Cancer Society summaries.
- NCI data show an approximately two- to threefold association for first-degree family history across several populations.
- Risk becomes greater when several relatives are affected.
- Younger age at diagnosis in affected relatives strengthens concern for inherited susceptibility.
- Family history should include both maternal and paternal relatives.
- Patterns of breast, ovarian, pancreatic, colorectal and other cancers can be relevant to genetic assessment.
- BRCA2 is one of the strongest established germline prostate-cancer susceptibility genes.
- EAU estimates a roughly 2.5- to 4.6-fold overall relative-risk range for BRCA2 carriers.
- The relative association can be much larger for early-onset prostate cancer.
- BRCA2-associated prostate cancer can also have more aggressive clinical features.
- BRCA2 carriage does not mean cancer is inevitable.
- HOXB13 variants are associated with hereditary prostate-cancer susceptibility.
- The HOXB13 G84E variant has been most extensively studied in men of European ancestry.
- ATM and CHEK2 are additional DNA-repair genes relevant to inherited susceptibility.
- Lynch syndrome mismatch-repair genes can also increase prostate-cancer risk.
- Common low-impact inherited variants can be combined into polygenic risk scores.
- Polygenic risk scores are associated with prostate-cancer probability but do not replace established clinical evaluation.
- Population incidence differs by ancestry.
- Men of African ancestry have higher observed incidence in several Western populations.
- Observed ancestry differences involve genetic, environmental, social and healthcare factors.
- Race should not be treated as a single biological cause.
- Obesity has a complex association with prostate cancer.
- Obesity is not consistently associated with greater overall prostate-cancer incidence.
- Some studies link obesity with high-grade disease and greater prostate-cancer mortality.
- Metabolic syndrome has mixed and generally weak evidence.
- Diabetes has shown inconsistent associations with prostate-cancer diagnosis.
- Smoking is not one of the strongest established causes of developing prostate cancer.
- Smoking is associated with more aggressive features and higher prostate-cancer mortality.
- EAU cites an approximately 24% higher relative risk of prostate-cancer death among current smokers in meta-analytic evidence.
- Some studies link very high dairy or calcium intake with a small increase in risk.
- Current evidence does not prove that eliminating dairy prevents prostate cancer.
- No specific diet is proven to prevent prostate cancer.
- Lycopene supplements are not proven prostate-cancer prevention.
- Vitamin E supplementation should not be used to prevent prostate cancer.
- The SELECT trial found increased prostate-cancer risk with vitamin E supplementation alone.
- Vasectomy is not supported as a meaningful prostate-cancer risk factor in current EAU guidance.
- Higher ejaculation frequency has been associated observationally with lower incidence.
- That association does not establish ejaculation frequency as a preventive treatment.
- Current EAU evidence does not show increased prostate-cancer risk from appropriately prescribed testosterone replacement in hypogonadal men.
- A risk factor does not diagnose prostate cancer.
- Risk factors influence when early detection is discussed.
- EAU suggests informed PSA testing from age 50 in men without additional recognized risk factors.
- EAU suggests starting at age 45 for men of African descent.
- EAU also suggests age 45 for men with qualifying family history.
- BRCA2 carriers can begin informed PSA testing discussions from age 40 under EAU guidance.
- The first PSA result can help determine future testing intervals.
- An elevated PSA does not automatically require biopsy.
- Repeat PSA, PSA density, MRI, risk calculators or biomarkers can refine risk before biopsy.
- Genetic counseling is appropriate before germline testing.
- Not every man needs germline genetic testing.
- The strongest family patterns for genetic evaluation include multiple affected relatives, early diagnoses and multiple related cancer types.
- Risk assessment should guide attention and testing—not create fear or certainty about an individual outcome.
Clinical bottom line: age, family history, inherited susceptibility and ancestry-associated population risk are far more useful for prostate-cancer risk assessment than most proposed dietary or lifestyle factors. The strongest risk factors cannot usually be changed, which is why their main clinical value is helping determine when PSA-based early detection, genetic counseling and closer evaluation should be discussed.
Medical disclaimer: This article provides general education about prostate-cancer risk and does not calculate an individual’s probability of developing cancer. Family history, ancestry, genetic results, PSA and other clinical information need to be interpreted together. Genetic testing can have implications for relatives and should be performed with appropriate counseling when indicated.
For the complete disease pathway, return to the Prostate Cancer hub. For how the disease may present clinically, see Prostate Cancer Symptoms. For the biomarker used in risk-adapted early detection, see PSA Testing. The next guide examines family history in greater depth, including how the number of affected relatives, degree of relationship and age at diagnosis modify prostate-cancer risk.
Evidence Sources
- European Association of Urology — Prostate Cancer: Epidemiology and Aetiology, including family history, ancestry, BRCA2, HOXB13, obesity, smoking, diet and environmental associations.
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: risk-adapted ages for informed PSA-based early detection and germline testing guidance.
- National Cancer Institute — Genetics of Prostate Cancer (PDQ): family-history risk, hereditary syndromes, BRCA2, HOXB13 and germline susceptibility.
- National Cancer Institute — Prostate Cancer Prevention (PDQ): age, family history, dietary associations, vitamin E and prevention evidence.
- American Cancer Society — Prostate Cancer Risk Factors: age, race and ethnicity, family history, inherited gene changes, obesity, smoking and dietary associations.
- American Cancer Society — Prostate Cancer Key Statistics: U.S. lifetime risk and age distribution.
